Ending infectious diseases, one day sooner
1Day Sooner leads campaigns in science, policy, and ethics to stop the world’s most harmful infectious diseases.
We envision a world where the risks taken by research participants are honored through maximally efficient and equitable use of research results.
That means involving ourselves in scientific, regulatory, and ethical discussions not only about clinical research, but also the products that come from it, whether it’s a vaccine, treatment, or new knowledge about an infectious disease.
News & Releases
-
Cooperative Participant Organization (CPO) Study Support for Challenge Trial Investigators
Our Cooperative Participant Organization (CPO) embeds 1Day Sooner staff scientists directly into study teams worldwide, especially in controlled human infection…
-
September 18, 2025
The death rays that guard life
We disinfect water before we drink it. Germicidal ultraviolet could make airborne diseases as rare as those carried by water.
-
September 15 2025
1Day Sooner Launches Cooperative Participant Organization to Aid Clinical Research
We’ve launched our Cooperative Participant Organization (CPO), a first-of-its-kind independent collaborative organization that supports early-phase, high-impact clinical trials driven by the experience of and involving healthy participants. Researchers at Leiden University, Malawi Liverpool Wellcome Research Programme, University of Oxford, and others are the first collaborators of 1Day Sooner’s CPO program. The CPO collaborates with institutions globally, with a current focus on Europe, North America, and Africa.
-
August 29, 2025
Human Challenge Studies with Wilbur H. Chen, MD and Jake Eberts
by PRIMR Research Ethics Imagined
This episode explores human challenge studies for shigellosis, examining their role in vaccine development and the ethical considerations surrounding intentional infection of healthy volunteers. Guests are Dr. Wilbur H. Chen, the Frank M. Calia, MD Endowed Professor and Chief of the Division of Geographic Medicine at the University of Maryland School of Medicine, and Jake Eberts of 1Day Sooner, who is a former participant in a Shigella challenge trial.
Volunteer
Volunteer for High-Impact Clinical Trials
1Day Sooner advocates for the interests of participants in intensive infectious disease trials to help test vaccines and enable other medical advances. Much of our work involves human challenge studies, where carefully screened, healthy participants volunteer to be infected with a disease in controlled conditions. Since our founding in 2020, over 40,000 people have signed up with us expressing interest in joining early phase medical research, including human challenge studies and other vaccine trials.